Antidote of CoronaVirus ?

What is Plasma Therapy: A possible treatment for Coronavirus ? 

Several countries, including India, are seriously looking at Plasma therapy as a potential treatment for Covid-19, the disease caused by the novel Coronavirus. Plasma therapy uses blood donated by recovered patients to introduce antibodies in those under treatment. We take a look at what convalescent plasma therapy is, the benifits and risks involved in the potential treatment, what past research says about it, and more.

As Covid-19 continues to wreck havoc across the globe, scients are racing to develop antidotes for the new coronavirus, which began infecting humans late last year. Scientists and researchers are exploring various avenues to come up with medical treatments that can fight the novel coronavirus. One such treatment that's in focus right now is Convalescent plasma Therapy.

After China and the US, India has given a go ahead for farming a protocol to conduct a clinic trial for Convalescent plasma therapy. The Therapy has been used experimentally in the past and so has become a ray of hope in the fight against the novel coronavirus pandemic.

In this article, we explain what the convalescent Plasma Therapy is the benifits and risks involved, what past research says and more.

What is Plasma Therapy? 

Plasma is the Liquid portion of blood that remains when all red and white blood cells and platelets have been removed. It was over a hundred years ago that Emil Behring was awarded the first Novel Prize for Physiology and medicine for his work demonstration that plasma could be used to treat diphtheria. 

Emil Behring

We know that the key component of plasma for treating infections is antibodies. Antibodies are Y-shaped proteins that are highly specific for whichever infection a person has previously encountered. They are produced in vast quantities by B cells of our immune system in order to bind to the invading virus and then target it for destruction. The concept of vaccination relies on stimulating antibody production to infections not yet met. In contrast, using convalescent plasma involves the transfer of antibodies from donors who have already mounted an immune response, thus offering immediate (but transient) protection to the recipient.


Convalescent plasma has been trialled as a therapy in previous Coronavirus outbreak. A few observational studies were conducted during the first  Sars Epidemic in 2003. These all reported improvement in patients after receiving convalescent plasma. However, these studies were largely case reports- not the most reliable type of evidence.

Convalescent Plasma treatment was also tested during the Ebola_Virus outbreak in 2013-2016. Several case reports showed promising results, but again, large-scale randomised trials were not performed. Still the World_Health_Organization published guidelines on appropriate use of plasma from recovered patients.


The handful of early reports in which COVID-19 patients have been treated with convalescent plasma have granted plenty of interest Each has concluded the plasma therapy is safe and improves patients outcome, but there are significant limitations to each of these studies. To begin with, each study has only treated a maximum of ten patients, so it's ompossible to know how the patients may have responded without treatment.



Risks Involved 

1. Transfer of blood substances: As the blood transfusion takes place, there are risks that an inadvertent infection might get transferred to the patient.
2. Enhance of Infection: The therapy might fail for some patients and can result in an enhanced form of the infection.
3. Effect on immune system: The antibody administration may end up suppressing the body's natural immune response, leaving a Covid-19 patient vulnerable to subsequent re-infection.

All above informations are trusted and published after researched.